Oscar Health price target raised to $20 from $10 at BofA

BofA analyst Adam Ron raised the firm’s price target on Oscar Health to $20 from $10 and keeps a Buy rating on the shares, stating that this quarter “delivers the proof point we’ve all been waiting for.” Oscar is now on track to deliver meaningful profitability in 2024 as well as generate free cash flow for the first time, lifting the financing overhang, says the analyst, who is raising earnings estimates following the Q4 outperformance.